KolateAI PharmaTech Inc Information

To improve trial success and treatment outcomes, pharma needs to predict how individual patients will respond to therapy. However, patient data from visit notes, labs, and imaging is fragmented and incomplete, making it costly and complex to build comprehensive patient profiles and generate accurate predictions. Our AI platform aggregates patient data, builds integrated patient histories, applies disease-specific models, and generates digital twins to quickly and inexpensively simulate and predict patient-level drug response, side effects, and disease risk. Pharmaceutical companies use our platform to enable trial enrichment, compare therapies in silico, and match patients to the right treatment. Across 11 validation studies, our platform has demonstrated over 90% accuracy in predicting patient-level clinical outcomes. We have two publications accepted and five under review. Our platform is therapeutic-area-agnostic and is being used by five global biopharmaceutical companies and three academic medical centers in metabolic disease, immunology, dermatology, and oncology, with expansion into neurology and pulmonology planned for 2026.